REFLAB ApS: Financial statements 2024
CVR: 15322586
Source: annual report 2024, Danish Business Authority
01/01/2024 – 31/12/2024
REFLAB ApS (CVR 15322586) has filed annual accounts for 2024. In 2024, the company reported a gross profit of DKK 5,921,822 and a net result of DKK 652,577 compared with DKK -935,624 the year before. That is an increase of 71.4% compared with the year before. Equity in the 2024 report amounted to DKK 1,157,382. The solvency ratio was 18.1%. The company had 8 employees in the financial year.
- Gross Profit
- DKK 5,921,822
- Profit/Loss
- DKK 652,577
- Equity
- DKK 1,157,382
- Total Assets
- DKK 6,380,226
- Employees
- 8
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2024 | - | 5.9 mio. | 653 t. | 1.2 mio. | 8 |
| 2023 | - | 3.5 mio. | -936 t. | 505 t. | 7 |
| 2022 | - | 3.2 mio. | -646 t. | 1.4 mio. | 7 |
| 2021 | - | 3.4 mio. | -341 t. | 2.1 mio. | 7 |
| 2020 | - | 1.9 mio. | -888 t. | 2.4 mio. | 6 |
Official annual report
Screen every Danish company
Combine filters on financials, industry, geography, property and risk, and instantly see which companies match.
Try company screeningEvents in 2024
REFLAB ApS has published its annual report for 2023. Gross profit came to DKK 3,455,886, and the net result was DKK -935,624.
About REFLAB ApS
REFLAB ApS is a Danish company of the type Anpartsselskab based in Hvidovre, founded in 1991. The company is registered under the industry Traditionelle, komplementære og alternative behandlingsformer. The company was previously named REFERENCELABORATORIET ApS. The management consists of Gert Pynt Andersen and Katrine Baumann Markussen. The company is owned by R-Biopharm AG. The company has 10 employees (2026). In 2025, the company reported a gross profit of DKK 4,582,184 and a net result of DKK -1,792,430 compared with DKK 652,577 the year before. Equity in the 2025 report amounted to DKK -635,048.